Empowering patients across Europe: an economic perspective



David McDaid

LSE Health & Social Care & European Observatory on Health Systems and Policies, London School of Economics

- E-mail:d.mcdaid@lse.ac.uk
- EPF, Brussels, March 07

Structure

- European and national context
- →Is there an economic case?
- Current challenges and potential pitfalls
- → Way forward


European Context

- →Ensuring a high level of health protection and promoting public health
- →Safeguarding patients from misleading information
- Common European Values on Health
- → Promoting choice for consumers
- →Improving the operation of the Single European Market

National Context


- Greater access/demand for info on disease and treatments
- →Increasing emphasis on patient choice
- Recognition of potential benefits of better informed individuals
- →Increasing use of cost-effectiveness info when considering health care interventions

H H D G C t The economic impacts of poor health range far and wide.....



1,811 Employees34% reported OAMonthly costs per person with OA at Council €111

Rabenda et al J Rheumatol 2006



Thomas & Morris *Brit J Psychiatry* 2003

npowermen

So can some of these costs be avoided through greater patient empowerment?

Empowerment: many dimensions

- Improved access to and use of information related to health
- →Greater say over choice of treatments and location where treatment delivered
- →Greater financial control over health care budgets
- Increased involvement in delivery of services
- →Increased (Public) involvement in process of determining effectiveness and cost effectiveness of interventions

Information and Choice

- Potentially significant quality of life and economic benefits - Wanless 'Fully Engaged'
- →Help encourage use of interventions that best meet patient needs.
- Improved concordance with treatment can potentially help improve long term outcomes
- →Potentially can help to reduce chance of harmful events
- Potentially help to reduce waste from unused medications/interventions


Drug Wastage

- →In the UK alone cost of wasted medications
 €290 million per annum
- →Rising 65% increase over four years
- →In primary care 60% of these medications for cardiovascular, central nervous system and respiratory disorders
- Primary reason because medication changed by prescriber - not suitable for individual could this be avoided?

Decision Aids

- Decision aids leaflets, DVDs, decision boards, websites, phone support etc
- → Some (limited) evidence on cost effectiveness
- →Use of blood chart to aid patients in treatment decisions on menstrual blood loss.
 €2110 per QALY gained compared with €2773 per QALY without chart (Van der Wilt et al 2004)
- → But Finnish study reported information prior to first consultation had no impact on costs or outcomes (Vuorma et al 2004)

Impact of decision aids on health service costs (England, 2001)



Kennedy et al , JAMA, 2002

Concordance

Poor concordance has health and economic consequence

- →e.g. essential heart transplant patients' maintain immunosuppressive therapy
- →Impact of quality of life of poor concordance with treatment for mild asthma may be negligible
- Adaptation of treatment may however fit better with individual lifestyles
- →Costs of additional treatment/diagnosis but may be offset by under use of some treatments



- Evidence on effectiveness and cost effectiveness of interventions to improve concordance surprisingly limited
- →One review (Elliot et al 2005) found
 - →45 comparative studies; 14 asthma; 12 psychiatric
 - → 33 educational interventions; 18 multi-intervention
 - →Methods often poor especially for costs
 - →Unable to reach definitive conclusions
- One large scale 36 month economic study underway on statin use in Germany (ORBITAL)

Choice

Reforms to financing can promote patient empowerment

Consumer directed health care

- Consumer directed health care
- Patients receive individual budgets to buy (some) services that best meet their needs:
 - Promotes independence and inclusion.
 - Offers opportunities for rehabilitation, education, leisure and employment ...
 - > ... but consumers may need support to make choices.
- Some experimentation with budgets across Europe for a range of client groups - older people, people with disabilities, mental health problems etc. Satisfaction levels good but little known about long term outcomes and costs

Inappropriate demand

- →Will greater levels of empowerment generate inappropriate demand for some interventions? (Avian Flu and Influenza Vaccines) (Health Security Issue)
- Media stories are a key driver of such events - fuelled further by more patient empowerment?

🔤 E-mail this to a friend

Printable version

Flu vaccine supply to be reviewed

The government is to consider again how best to guarantee seasonal flu vaccines for those at risk after stocks run low.

It blames the shortage on demand outstripping supply, most likely fuelled by public concerns about the threat of a possible bird flu pandemic.



The vaccine does not protect against bird flu

But Health Secretary Patricia Hewitt said GPs may have been giving the vaccine to the worried well rather than those most at risk as recommended.

She said she would review the ordering situation as a matter of urgency.

In the meantime, the Department of Health is advising GPs in England to use remaining stocks only on those at highest risk.

They include the over-65s and people with health problems such as heart disease, asthma and diabetes.

The vaccine does not protect against avian flu, but offers some protection against common winter influenza. BBC NEWS:VIDEO AND AUDIO MPs react to the vaccine shortage

VIDE0

SEE ALSO:

- Q&A: Flu jabs
 22 Nov 05 | Health
- No flu vaccine shortage in Wales
 22 Nov 05 | Wales
- 'No repeat' of flu jab shortage 03 Oct 05 | Northern Ireland
- Flu jab call for the most at risk 03 Oct 05 | Health
- Flu database will help plan care 06 Oct 05 | Nottinghamshire
- Nurses 'not taking flu vaccine' 19 Sep 05 | Merseyside

RELATED BBC LINKS: Flu

RELATED INTERNET LINKS:

- Department of Health
- British Medical Association

The BBC is not responsible for the content of external internet sites

TOP HEALTH STORIES

- Hospital car parks make millions
- Supermarkets to host GP


He who shouts loudest

- What if product is not considered to be cost effective at national level? (Beta interferon)
- This may lead to both an inefficient and inequitable allocation of resources.
- Some groups more vocal than others some issues more 'attractive'
- Every decision to provide access to a treatment potentially means that resources are not available to treat someone else

Empowerment for all?

- Capacity to assess information health literacy
- How is information presented? Who funds this? - Information or Advertising?
- Are all reasonable alternatives (drug, technology, health promotion etc) provided etc
- → How to overcome information inequities?

Use of Internet in Europe



% population

How to identify bogus information?



Quackwatch[™]

Your Guide to Quackery, Health Fraud, and Intelligent Decisions Operated by <u>Stephen Barrett, M.D</u>.

> How to Navigate This Site | What's New? | Ask a Question | Make a Comment | Report a Fraud Join Discussion List | Join Advisory Board | Get Free Newsletters | Visit Our Afrilated Sites - 🔽 Go

About Quackwatch 🖬

- <u>Mission Statement</u> (updated 7/6/06)
- Tips for Navigating Our Web Sites (updated 11/20/04)
- <u>Recently Posted Articles</u>
- Who Funds Quackwatch? (updated 5/15/06)
- Scientific and Technical Advisory Board (152 members, updated 3/28/03)
- Legal Advisory Board (28 members, updated 3/31/06)
- Honors and Awards (70+) Given to Quackwatch (slow-loading page, updated 7/11/04)
- Frequently Asked Questions (FAQs) (updated 3/24/06)
- <u>Cheers and Jeers from Quackwatch Visitors</u> (updated 10/6/04) FEATURE
- Special Message for Cancer Patients Seeking Alternative Treatment (updated 3/22/06) FEATURE
- Join the Health Fraud Discussion List (updated 7/12/04) FEATURE
- Quackwatch auf Deutsch || Quackwatch en Français || Quackwatch em Português

About Dr. Barrett 🖬 🖪

- <u>Biographical Sketch and Contact Information</u> (updated 3/25/06)
- Curriculum Vitae (updated 12/2/04)
- Books and Book Chapters (updated 3/25/06)
- Frequently Asked Questions (FAQs) (updated 8/14/04)
- Biography Magazine Interview (posted 11/17/98)

We accept donations to support our work.

Sponsored Links to Recommended Vendors

Check a doctor's credentials at <u>HealthGrades</u>

<u>ConsumerLab.com</u>: Evaluates the quality of dietary supplement and herbal products.

<u>Netflix</u>: Free 2-week trial of DVD rentals by mail; 55,000 titles available.

Hot Topics

Sear

or search all our sites or search with Google



What can patient groups do?

Actions

→Information on how to make best use of existing health care treatments

- →Help communicate understanding of risks and benefits of alternative drug and non drug treatment options
- Dook at impacts and consequences beyond health care systems
- Make careful use of evidence base when presenting case - don't oversell
- →Be aware decisions not made in vacuum decisions have consequences for rest of health service

Messages for other groups

- → General Public:
 - → Messages on preventive actions
 - →Greater awareness and early identification of health risks
 - Better understanding of potential treatment options and their risks/benefits for future patients
- → Role of doctors/pharmacists vital
- National and European level information systems e.g. EU Health Portal; NHS Direct

5

What information gaps do we need to plug?

Substantial information deficit

Remarkably the evidence base on the value for money of empowerment and access to information limited

Need for careful controlled prospective and long term monitoring of of different interventions - context

→Including analysis of resource use and consequences both within and outside the health sector

To sum up....

- There are potential health and economic gains to be made by improving access to information
- But much is still unknown careful evaluation is required
- Enhanced access to information alone is insufficient requires multiple interventions
- Important to think about minimise negative consequences/ inappropriate demand?
- Think about cost effectiveness not just effectiveness!